İşlekel, Sertaç

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7189
Name Variants
Işlekel, Sertaç
Islekel, S.
Islekel, Sertac
İşlekel, Sertaç
Job Title
Email Address
sertac.islekel@gmail.com
Main Affiliation
07.01. Health Management
Status
Former Staff
Website
ORCID ID
Scopus Author ID
56619823200
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
CVL-5452-2022

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
1
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

25

Citations

817

h-index

14

Go to Scopus profile
Documents

31

Citations

661

Go to WoS profile
Scholarly Output

3

Articles

3

Views / Downloads

2/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

16

Scopus Citation Count

15

Patents

0

Projects

0

WoS Citations per Publication

5.33

Scopus Citations per Publication

5.00

Open Access Source

0

Supervised Theses

0

JournalCount
Bıoanalysıs1
Dna Repaır1
Journal of Neuropathology And Experımental Neurology1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2022 - 20233
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Citation - WoS: 5
    Citation - Scopus: 3
    Urinary 8-Hydroxy Levels Are Elevated in Patients With Idh1-Wildtype Glioblastoma and Are Associated With Tumor Recurrence in Gliomas
    (Elsevier, 2023) Tuna, Gamze; Bekar, Nazli Ecem Dal; Islekel, Sertac; Islekel, Gul Huray
    2021 World Health Organization (WHO) Central Nervous System (CNS) Tumor Classification includes molecular diagnostic parameters such as isocitrate dehydrogenase (IDH) mutation or 1p19q codeletion status, in addition to the classical histological classification. Several studies have revealed that patients with IDH1 mutation have a longer survival rate compared to wildtype individuals. In glioma cells, increased oxidative stress has been identified. However, till now, the relation between oxidative stress levels and IDH1 mutation status in those patients was not examined. Therefore, the aim of this study was to investigate the urinary levels of oxidatively induced DNA damage products, 8-hydroxy-2 '- deoxyguanosine (8-OH-dG), (5 ' R) and (5 ' S)-8,5 '-cyclo-2 '-deoxy-adenosines (R-cdA and S-cdA) as reliable oxidative stress markers in patients with IDH1-wildtype (n = 20) and IDH1-mutant (n = 22) glioma. Absolute quantification of 8-OH-dG, R-cdA and S-cdA was achieved by liquid chromatography-tandem mass spectrometry with isotope dilution. The levels of 8-OH-dG were significantly greater in IDH1-wildtype glioma patients than those in IDH1-mutant ones (p = 0.017). No statistically significant difference was observed for R-cdA and S-cdA levels. 8-OH-dG levels were positively correlated with patients' tumor recurrence in all patients (r = 0.382, p = 0.014). The mutation status of glioma is well correlated with oxidative stress. Examination of noninvasively measured oxidative DNA damage products along with IDH1 mutation status in glioma patients, might be particularly important in terms of evaluating and monitoring the effectiveness of treatment.
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 1
    Development and Validation of an Lc-ms/Ms Method for D- and L-2 Acid Measurement in Cerebrospinal Fluid, Urine and Plasma: Application To Glioma
    (Future Sci Ltd, 2022) Dal-Bekar, Nazli Ecem; Tuna, Gamze; Islekel, Sertac; Islekel, Gul Huray
    Aim: IDH mutations have been identified as frequent molecular lesions in several tumor types, particularly in gliomas. As a putative marker of IDH mutations, elevated D-2-HG has been reported in glioma, acute myeloid leukemia and intrahepatic cholangiocarcinoma. Excessive production of L-2-HG has also been described in renal cell carcinoma and 2-hydroxyaciduria. Materials & methods: The authors present a fully optimized stable isotope dilution multiple reaction monitoring method for quantification of D-/L-2-HG using LC-MS/MS. This is the first method validation study performed on cerebrospinal fluid, plasma and urine demonstrating clinical applicability with samples from glioma patients. Results & conclusion: This method validation study showed high accuracy and precision with low limit of detection and limit of quantification values. The authors believe that the presented approach is highly applicable for basic and clinical research on related pathologies.
  • Thumbnail Image
    Article
    Citation - WoS: 10
    Citation - Scopus: 11
    Minimally Invasive Detection of Idh1 Mutation With Cell-Free Circulating Tumor Dna and D-2 D/L-2-hydroxyglutarate Ratio in Gliomas
    (Oxford Univ Press Inc, 2022) Tuna, Gamze; Dal-Bekar, Nazli Ecem; Akay, Ali; Ruksen, Mete; Islekel, Sertac; Islekel, Gul Huray
    Isocitrate dehydrogenase-1 (IDH1) mutation is accepted as one of the earliest events in tumorigenesis in gliomas. This mutation causes preferential accumulation of D- relative to L-enantiomer of 2-hydroxyglutarate (2-HG). Minimally invasive techniques to detect IDH1 mutation may prove useful for clinical practice. We adopted 2 different diagnostic approaches to detect IDH1 mutation status in glioma patients: Evaluation of D- and L-2-HG levels in cerebrospinal fluid (CSF), urine, and plasma, and identification of IDH1 mutation using cell-free circulating tumor DNA (ctDNA) in CSF and plasma. Forty-nine glioma patients in different stages were included. Levels of D- and L-2-HG were determined using liquid chromatography-tandem mass spectrometry; IDH1 R132H mutation was determined by digital-PCR. D-2-HG levels and D/L-2-HG ratio (rDL) in CSF and rDL in plasma were significantly higher in the mutant group than in the wild-type group (p = 0.029, 0.032, 0.001, respectively). The IDH1 mutation detection rates in CSF- and plasma-ctDNA were 63.2% and 25.0%, respectively. These data indicate that D-2-HG values in CSF and rDL in plasma and CSF can be considered as significant contributors to the identification of IDH1 mutation status. In addition, detection of IDH1 mutation in CSF-ctDNA from glioma patients provides a basis for future use of ctDNA for minimally invasive clinical assessment of gliomas.